About Us

Latest News & Exhibitionborder

BGI Genomics’ CEO Yin Ye presents ambitious plans at the JP Morgan Healthcare Conference in San Francisco

Today at the 36th J.P. Morgan Healthcare Conference, Ye Yin, CEO of BGI Genomics, announced that BGI Genomics has successfully sequenced the genome of over 10,000 human samples since it launched the industry’s lowest priced Whole Genome Sequencing service at US$600, using the BGISEQ-500, BGI’s own sequencing platform.

Ye Yin went on to present two exiting new BGI initiatives: The 2020 Program and the Life Periodic Plan, both of which received strong interest from his audience.

Over 10,000 human WGS samples have been sequenced with the BGISEQ-500 for just US$600 each, the industry’s lowest price.

Monday, June 25, 2018/Author: dardeshana/Number of views (6)/Comments (0)/ Article rating: No rating
Categories: Uncategorized
Tags:

CANADA AND CHINA PARTNERING TO DEVELOP DIAGNOSTICS TESTS FOR PRETERM BIRTH

Shenzhen, China and Toronto, Canada, November 30, 2017 ‒ BGI and the Lunenfeld-Tanenbaum Research Institute, part of Sinai Health System, today announced the signing of a Memorandum of Understanding (MOU) outlining their intention to collaborate on the development a genomics-based diagnostic test for the early identification of women at risk for pre-term birth and other pregnancy complications. The non-invasive test will be based on genomic information from easy to obtain blood samples.
Monday, June 25, 2018/Author: dardeshana/Number of views (4)/Comments (0)/ Article rating: No rating
Categories: Uncategorized
Tags:

BGISEQ-500 NIFTY® Kits Receive CE mark

December 12, 2017 BGI’s NIFTY® test kit for fetal chromosome aneuploidy has obtained EU Medical Device CE Certification issued by the BSI (British Standards Institution). This adds to the existing CE certifications already achieved for the BGISEQ-500 platform, its ancillary reagents and nucleic acid extraction kit.

The NIFTY® Test uses next-generation sequencing technology to estimate the risk of a fetus having Down’s syndrome (T21), Edwards’ syndrome (T18) and Patau’s syndrome (T13), by analyzing cell-free fetal DNA from a sample of maternal blood from 10 weeks’ gestation. The test also screens for certain sex chromosomal disorders and deletion syndromes. The NIFTY® Test has processed more than 2,500,000 samples globally as of the end of 2017*.

Wednesday, June 20, 2018/Author: dardeshana/Number of views (8)/Comments (0)/ Article rating: No rating
Categories: Uncategorized
Tags:

BGI expands Long-Read sequencing capacity with 10 new Sequel systems

BGI expands its long-read sequencing capacity with the purchase of 10 new PacBio Sequel systems. Customers will benefit from exceptional data quality and reduced turn-around timed for plant/animal/microbial sequencing, conservation biology and other long-read services. Featured today in GEN and on GenomeWeb.
Wednesday, June 20, 2018/Author: dardeshana/Number of views (30)/Comments (0)/ Article rating: No rating
Categories: Uncategorized
Tags:

BGISEQ-500 & NIFTY Kits receive Thai FDA import certificate

9th Feb 2018, BGISEQ-500 and NIFTY Kit received the import certificate from Thai Food and Drug Administration (Thai FDA). This follows on the achievement of this platform and kit being awarded the EU medical device CE certificate at the end of 2017.
Wednesday, June 20, 2018/Author: dardeshana/Number of views (7)/Comments (0)/ Article rating: No rating
Categories: Uncategorized
Tags:
RSS
12345